RAC1 and prostate carcinoma: Treatment of 22Rv1 human prostate cancer cells with 5, 10 or 20 μM AZA1 for 60 min dose-dependently reduced Rac1 activity significantly by 45% (p<0.022), 70.4% (p<0.004) and 85.7% (p<0.002), respectively, compared to 20 μM NSC23766 (Figure 2A left panel).